Siga Technologies ( (SIGA) ) has released its Q3 earnings. Here is a breakdown of the information Siga Technologies presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company specializing in the development of antiviral medicines to combat infectious diseases, with a primary focus on orthopoxviruses. The company is known for its flagship product, TPOXX, which is approved for the treatment of smallpox and other related diseases in various countries.
In its latest earnings report, SIGA Technologies announced financial results for the three and nine months ending September 30, 2025. The company reported $86 million in product revenues and $33 million in pre-tax operating income for the first nine months of the year. The CEO emphasized the company’s ongoing efforts to secure new procurement contracts with the U.S. and international governments.
Key financial highlights include a significant increase in product sales, which reached $85.8 million for the nine-month period, up from $53.5 million in the previous year. Despite this growth, the company faced a net loss of $6.4 million for the third quarter, attributed to a decrease in quarterly revenues and increased research and development expenses. Notably, SIGA’s TPOXX product secured regulatory approval in Japan, marking a significant milestone for the company’s international expansion.
Looking ahead, SIGA Technologies remains focused on expanding its partnerships and securing additional contracts to bolster its revenue base. The management is optimistic about building on its track record of successful collaborations with government entities to support its growth in the coming years.